Patients with systemic lupus erythematosus may develop premature atherosclerosis, notably coronary artery disease. A group of 10 patients with peripheral vascular disease presenting with intermittent claudication or gangrene were studied from a group of 563 patients followed prospectively at the Wellesley Hospital Lupus Clinic. These 10 patients were compared with the next lupus clinic patient matched for age and sex, with respect to demographic characteristics and risk factors.
Arterial vascular disease in systemic lupus erythematosus has a number of pathogenic mechanisms, including arteritis, intravascular coagulation frequently associated with a lupus anticoagulant'-3 and, in chronic lupus, atherosclerosis. 4 The last mechanism is currently recognised as a major cause of death and morbidity in patients with systemic lupus erythematosus.5 Coronary artery atherosclerosis has been widely reported", although peripheral vascular disease has been infrequently described. We report here 10 cases of peripheral vascular disease in a population of patients attending a lupus clinic, and discuss the risk factors associated with its development. Patients Peripheral vascular disease was defined as one of intermittent claudication, absent peripheral pulses, gangrene, and angiographic or Doppler evidence of large vessel disease. Vascular disease due to vasculitis was excluded. Patients with peripheral vascular disease were matched to control subjects who were defined as the next patient of similar age and sex with systemic lupus erythematosus registered at the clinic.
The characteristics of patients and controls were reviewed for age at the diagnosis of peripheral vascular disease, sex, duration of systemic lupus erythematosus to time of diagnosis of peripheral vascular disease, the site involved, presence of angina, myocardial infarction or cerebrovascular disease, vascular surgery performed, and date of death. Lupus activity was assessed by the lupus activity criteria count12 at the time of diagnosis of peripheral vascular disease. Renal involvement (red blood cell count >5/high powered field, proteinuria >0 5 g/day, casts, creatinine >120 [imol or abnormal renal biopsy specimen), central nervous system involvement (psychosis, seizures or severe headaches unresponsive to narcotic analgesia) and vasculitis (retinal, vasculitic skin or major organ lesions, and Raynaud's phenomenon) before the diagnosis of peripheral vascular disease were recorded. The partial thromboplastin time at the diagnosis of peripheral vascular disease was noted. Antibodies to cardiolipin were measured by the enzyme linked immunosorbent assay (ELISA) method'3 using the SELISA anti-cardiolipin IgG antibodies assay kit (Walker Laboratories). The dose and duration of treatment with prednisone was calculated.
The presence of classical risk factors for atherosclerosis was also recorded, including: diabetes (fasting blood sugar >7-0 mmol/l, two hours after a meal >110 mmol/l); hyperlipidaemia (cholesterol >7 0 mmol/l, triglycerides >1-8 mmol/l), or hypertension in the year before diagnosis of peripheral vascular disease, family history of coronary heart disease in a first degree relative and use of oral contraceptives.
Other potential risk factors associated with excess morbidity in patients with systemic lupus erythematosus were assessed in the year prior to the diagnosis of peripheral vascular disease, including pericarditis, myocarditis, endocarditis, and congestive heart failure. In this clinic population of patients with systemic lupus erythematosus, 41% of 27 autopsies had evidence of significant atherosclerosis of coronary arteries and the aorta.14 This total included patients without clinical features of ischaemic heart disease. Twenty per cent of all deaths were due to vascular events (myocardial infarctions) and 50% of deaths were in patients who had had systemic lupus erythematosus for more than two years.
Previously we identified 45 patients at our lupus clinic who had angina and myocardial infarctions and found the sytemic lupus erythematosus to be quiescent at the time of the vascular event (by lupus activity criteria count). Compared with the clinic population, an increased incidence of pericarditis, myocarditis, congestive heart failure and hypertension was found in these patients, as well as hyperlipidaemia, hyperglycaemia, diabetes, and increased average cortisone use. 6 Coronary atherosclerosis is therefore well reported in patients with systemic lupus erythematosus and a relationship with length of disease, duration of corticosteroid use, and other risk factors for atherosclerosis has been noted.
Peripheral vascular disease due to atherosclerosis has only been rarely reported. DePalma'5 described three patients with well controlled systemic lupus erythematosus who developed symptomatic peripheral vascular disease of the feet which required an operation. The criteria for diagnosis of systemic lupus erythematosus were not given. The patients had been treated with prednisone (5-12 mg daily) for 1-10 years. Two smoked and the results of the operation were good. Apart from this, other reports have been of vasculitis of the foot vessels presenting suddenly and catastrophically, usually with gangrene, and accompanied by very active systemic disease.16 17 This study was of 10 subjects who illustrated the general nature of atherosclerosis in patients with systemic lupus erythematosus. In addition to symptomatic peripheral vascular disease, most patients had coronary artery disease. The peripheral vascular disease developed at a younger age in these patients than in the general population. It 
